Leaflet: information for the user
Meloxicam pensa 15 mg tablets EFG
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
If you experience any side effects, consult your doctor, even if they are not listed in this leaflet. See section 4.
Meloxicam belongs to a group of medications called nonsteroidal anti-inflammatory drugs (NSAIDs)
used to reduce inflammation and pain in joints and muscles.
Meloxicam is indicated for adults and children 16 years of age and older.
Meloxicam is used for:
- rheumatoid arthritis
- ankylosing spondylitis.
Do not take Meloxicam Pensa if:
If you are unsure about any of the above situations, please contact your doctor.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Meloxicam Pensa.
Warnings
Medications like Meloxicam Pensa may be associated with a slight increase in the risk of heart attack ("myocardial infarction") or stroke ("cerebral infarction"). Any risk is greater at high doses and with prolonged treatment. Do not take more than the recommended dose. Do not take Meloxicam Pensa for longer than prescribed (see section 3 "How to take Meloxicam Pensa").
If you have heart problems, a previous stroke, or if you think you may be at risk of these diseases, you should discuss treatment with your doctor or pharmacist. For example, if you:
Stop taking Meloxicam Pensa immediately as soon as you notice bleeding (causing black stools) or ulcers in your digestive system (causing abdominal pain).
Severe skin eruptions that can be life-threatening (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been described with the use of Meloxicam Pensa, appearing initially as red, circular spots with a central blister.
Other signs that may appear include mouth, throat, nasal, genital, and conjunctivitis (swollen and red eyes).
These life-threatening skin eruptions, often accompanied by flu-like symptoms, may progress to form widespread blisters or skin peeling.
The highest risk period for the appearance of severe skin reactions is during the first weeks of treatment.
If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of Meloxicam Pensa, do not use Meloxicam Pensa again at any time. If you develop a rash or these symptoms on your skin, stop taking Meloxicam Pensa and immediately see a doctor and inform them that you are taking this medication.
Meloxicam Pensa is not suitable if you need to relieve acute pain immediately.
Meloxicam Pensa may mask the symptoms of an infection (e.g., fever). If you think you may have an infection, you should see a doctor.
If you have ever experienced a fixed drug eruption (round or oval patches with redness and swelling of the skin that often reappear in the same place, blistering, urticaria, and itching) after taking meloxicam or other oxicam derivatives (e.g., piroxicam).
Precautions for use
Since treatment will need to be adjusted, it is essential to seek advice from your doctor before taking Meloxicam Pensa in the following cases:
Taking Meloxicam Pensa with other medications
Since Meloxicam Pensa may affect or be affected by other medications, inform your doctor or pharmacist if you are taking, have taken, or may need to take any other medication.
Specifically, please inform your doctor or pharmacist if you are taking/have taken or have used any of the following medications:
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is:
Acute osteoarthritis:
7.5 mg (half tablet) once a day. This can be increased to 15 mg (one tablet) once a day.
Rheumatoid arthritis:
15 mg (one tablet) once a day. This can be reduced to 7.5 mg (half tablet) once a day.
Ankylosing spondylitis:
15 mg (one tablet) once a day. This can be reduced to 7.5 mg (half tablet) once a day.
Do not exceed the maximum recommended daily dose of 15 mg.
If any of the situations described under the title “Warnings and precautions” affect you, your doctor may limit your dose to 7.5 mg (half tablet) once a day.
Older patients
If you are an older person, the recommended dose in long-term treatment for rheumatoid arthritis and ankylosing spondylitis is 7.5 mg (half tablet) once a day.
Patients at increased risk of adverse reactions
If you are a patient at increased risk of adverse reactions, your doctor will start treatment at a dose of 7.5 mg (half tablet) per day.
Renal insufficiency
If you are a patient on dialysis with severe renal insufficiency, your dose should not exceed 7.5 mg (half tablet) per day. In patients with mild to moderate renal insufficiency, dose reduction is not necessary.
Hepatic insufficiency
In patients with mild to moderate hepatic insufficiency, dose reduction is not necessary.
Use in children and adolescents
Meloxicam should not be administered to children and adolescents under 16 years old.
Consult your doctor or pharmacist if you estimate that meloxicam's action is too strong or weak, or if after several days you do not notice any improvement.
Administration form
Oral route.
Tablets should be swallowed with water or other beverage during meals in a single daily dose.
If you take more Meloxicam than you should
If you have taken too many tablets or suspect an overdose, contact your doctor or go to the nearest hospital immediately.
Common symptoms associated with acute NSAID overdose are:
These symptoms usually improve when meloxicam is stopped.Gastrointestinal bleeding may occur.
Severe intoxication may cause severe adverse reactions (see section 4):
skin reactions
If you have taken more meloxicam than you should, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount used. It is recommended to bring the packaging and the medication leaflet to the healthcare professional.
If you forgot to take Meloxicam
Do not take a double dose to compensate for the missed doses.Simply take the next dose at the usual time.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Stop taking Meloxicam Pensa and consult your doctor or the nearest hospital immediately if you notice:
Any allergic reaction (hypersensitivity) that may appear in the form of:
Erythema multiforme is a severe skin allergic reaction that causes patches, red rashes or purple areas with blisters. It can also affect the mouth, eyes, and other moist areas of the body.
Any gastrointestinal side effect, especially:
Bleeding in the digestive tract (gastrointestinal hemorrhage), the formation of ulcers or a hole in the digestive system (perforation) can sometimes be severe and potentially fatal, especially in older people.
If you have previously experienced any symptoms of the digestive system due to prolonged use of NSAIDs, seek medical advice immediately, especially if you are an elderly person. Your doctor may monitor your progress while you are on treatment.
If you experience vision changes, do not drive or use machines.
General side effects of nonsteroidal anti-inflammatory drugs (NSAIDs)
The use of some nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with a slight increase in the risk of arterial occlusion (arterial thrombotic events), such as heart attack (myocardial infarction) or stroke (apoplexy), particularly at high doses and with long-term treatment.
Cases of fluid retention (edema), high blood pressure (hypertension), and heart failure (cardiac failure) have been reported associated with NSAID treatment.
The most common side effects observed affect the gastrointestinal tract (gastrointestinal events):
After NSAID administration, the following side effects have been reported:
Less frequently, gastric inflammation (gastritis) has been observed.
Side effects of meloxicam - active substance of Meloxicam Pensa
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Rare: may affect up to 1 in 100 people
Rare: may affect up to 1 in 10,000 people
These side effects may increase the risk of infection and cause symptoms such as bruises or nosebleeds.
Very rare: may affect up to 1 in 10,000 people
Frequency not known: the frequency cannot be estimated from the available data
Side effects caused by other nonsteroidal anti-inflammatory drugs (NSAIDs), which have not yet been seen after taking Meloxicam Pensa
Changes in the structure of the kidney that cause acute kidney failure:
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine
Keepthis medicationout of the sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration datethat appears on the blister pack and on the outer packaging. The expiration date is the last day of the month indicated.
Do not dispose of medications through the drains or in the trash. Dispose of the containers and
any unused medications at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and unused medications. By doing
this, you will help protect the environment.
Composition of Meloxicam pensa
The active ingredient is meloxicam. Each tablet contains 15 mg of meloxicam
The other components (excipients) are: sodium citrate, microcrystalline cellulose, lactose monohydrate, povidone, anhydrous colloidal silica, magnesium stearate, carboxymethylcellulose sodium (potato type A).
Appearance of the product and content of the packaging
Yellow, biconvex, scored, and marked with the code “M1” on one face, cylindrical tablets
Meloxicam Pensa 15 mg tablets are presented in packs containing 20 tablets.
Holder of the marketing authorization
Towa Pharmaceutical, S.A.
C/ de Sant Martí, 75-97
08107 Martorelles (Barcelona)
Spain
Responsible for manufacturing
Laboratorios Cinfa, S.A. c/Olaz-Chipi, 10. 31620 Huarte- Pamplona
Last review date of this leaflet: May 2023
The detailed information of this medicine is available on the website of the Spanish Agency of Medicaments and Sanitary Products (AEMPS)
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.